伴侣动物术后疼痛管理治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Companion Animal Postoperative Pain Management Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月08日 | 出版商:

Global Market Insights Inc. | 英文 229 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年，全球伴侣动物术后疼痛管理治疗市场价值为1.335亿美元，预计在预测期内复合年增长率为6.5%。伴侣动物外科手术频率的增加推动了市场的扩张。随着宠物数量的激增和兽医护理的发展，对高效的术后疼痛管理解决方案的需求不断增加。例如，美国宠物产品协会 (APPA) 报告称，美国宠物拥有量已飙升至 8,500 万隻，每年都有许多宠物接受手术。外科手术的增加强调了有效疼痛管理的迫切需要，强调了治疗在促进动物福利和復原方面的作用。

整个伴侣动物术后疼痛管理治疗产业根据药物类别、给药途径、适应症、动物类型、配销通路和地区进行分类。

伴侣动物术后疼痛管理治疗市场依药物类别分为非类固醇抗发炎药、鸦片类药物、麻醉剂、α2 激动剂和其他类别。 2023年，非类固醇抗发炎药领域以1.037亿美元的估值引领市场。非类固醇类抗发炎药物 (NSAID) 因其在减轻宠物疼痛和发炎方面的功效和安全性得到证实而引领市场。它们在兽医处方中占有很大份额，凸显了它们的突出地位，强调了它们在术后护理中的关键作用。 NSAIDs 在临床应用中建立的声誉，加上药物配方的不断创新，巩固了其领先的市场地位。

根据给药途径，市场分为口服、肠胃外和外用部分。 2023年，口腔细分市场以57.1%的主导份额占据市场主导地位。口腔部分的突出之处在于其方便、直接给药和有效缓解疼痛。兽医和宠物主人青睐口服疗法（无论是片剂、胶囊或口服混悬液）来控制术后疼痛，因为它们比注射或外用药更容易给药。该领域的主导地位得益于兽医实践中疼痛管理意识的提高以及口服药物配方的创新，以提高功效和安全性。

2023年，美国在北美伴侣动物术后疼痛管理治疗市场中处于领先地位，销售额达5,920万美元，预计未来几年将出现良好的成长。北美的领先地位归功于其先进的兽医基础设施、高宠物拥有率以及强劲的研发投资。该地区强大的医疗保健框架和尖端疼痛管理解决方案的迅速采用扩大了其市场份额。人们对改善宠物生活品质的日益关注，以及宠物主人对有效疼痛管理的认识不断提高，刺激了对先进治疗方法的需求。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 11 章：公司简介

Assisi Animal Health
Bayer AG
Bimeda Animal Health
Boehringer Ingelheim International GmbH
Ceva Sante Animale
Chanelle Pharma Group
Dechra Pharmaceuticals
Elanco Animal Health Incorporated
Merck Animal Health
Norbrook
SAVA Vet
Vetoquinol S.A.
Virbac Group
Zoetis Inc.

简介目录

Product Code: 10730

The Global Companion Animal Postoperative Pain Management Therapeutics Market was valued at USD 133.5 million in 2023 and is projected to grow at a CAGR of 6.5% during the forecast period. The market's expansion is driven by the rising frequency of surgical procedures in companion animals. As pet ownership surges and veterinary care evolves, there's an escalating need for efficient post-surgery pain management solutions. For example, the American Pet Products Association (APPA) reports that pet ownership in the U.S. has soared to 85 million, with many pets undergoing surgeries each year. This increase in surgical procedures underscores the critical need for effective pain management, emphasizing the role of therapeutics in promoting animal welfare and recovery.

The overall companion animal postoperative pain management therapeutics industry is classified based on the drug class, route of administration, indication, animal type, distribution channel, and region.

The market for companion animal postoperative pain management therapeutics is segmented by drug class into NSAIDs, opioids, anesthetics, alpha-2 agonists, and other categories. In 2023, the NSAIDs segment led the market with a valuation of USD 103.7 million. Nonsteroidal anti-inflammatory drugs (NSAIDs) lead the market due to their proven efficacy and safety in alleviating pain and inflammation in pets. Their prominence is underscored by their substantial share in veterinary prescriptions, emphasizing their pivotal role in postoperative care. NSAIDs' established reputation in clinical applications, paired with continuous innovations in drug formulations, solidifies their leading market position.

The market is divided into oral, parenteral, and topical segments based on the route of administration. In 2023, the oral segment commanded the market with a dominant share of 57.1%. The oral segment's prominence stems from its convenience, straightforward administration, and effective pain alleviation. Veterinarians and pet owners favor oral therapeutics-be it tablets, capsules, or oral suspensions-for postoperative pain management due to their ease of administration over injectables or topicals. The segment's dominance is bolstered by heightened awareness of pain management in veterinary practices and innovations in oral drug formulations that enhance efficacy and safety.

In 2023, the U.S. led the North American market for companion animal postoperative pain management therapeutics, accounting for USD 59.2 million, with promising growth anticipated in the coming years. North America's leadership is attributed to its advanced veterinary infrastructure, high rates of pet ownership, and robust investments in R&D. The region's strong healthcare framework and the swift adoption of cutting-edge pain management solutions amplify its market share. An intensified focus on improving pets' quality of life, alongside rising awareness among pet owners about effective pain management, fuels the demand for advanced therapeutics.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising awareness of animal welfare
  - 3.2.1.2 Increasing pet ownership
  - 3.2.1.3 Development of novel therapeutics
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Adverse effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 NSAIDs
5.3 Anesthetics
5.4 Opioids
5.5 Alpha-2 agonists
5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Parenteral
6.4 Topical

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Dogs
7.3 Cats
7.4 Other animal types

Chapter 8 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Orthopedic surgery
8.3 Soft tissue surgery
8.4 Dental surgery
8.5 Oncologic surgery
8.6 Other surgeries

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Veterinary hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 Saudi Arabia
- 10.6.2 South Africa
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa